Fidelity Investments
JANX icon

Fidelity Investments’s Janux Therapeutics JANX Stock Holding History

Fidelity Investments’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.1M Sell
2,412,825
-122,899
-5% -$1.78M ﹤0.01% 1642
2026
Q1 		$35.2M Sell
2,535,724
-976,660
-28% -$13.4M ﹤0.01% 1561
2025
Q4 		$48.5M Sell
3,512,384
-5,543,678
-61% -$130M ﹤0.01% 1458
2025
Q3 		$221M Buy
9,056,062
+167,320
+2% +$4.07M 0.01% 797
2025
Q2 		$205M Buy
8,888,742
+4,670
+0.1% +$123K 0.01% 809
2025
Q1 		$240M Buy
8,884,072
+214,131
+2% +$8.07M 0.02% 731
2024
Q4 		$464M Buy
8,669,941
+845,266
+11% +$44.7M 0.03% 498
2024
Q3 		$355M Buy
7,824,675
+47,075
+0.6% +$2.05M 0.02% 601
2024
Q2 		$326M Buy
7,777,600
+28,591
+0.4% +$1.34M 0.02% 608
2024
Q1 		$292M Buy
7,749,009
+3,077,796
+66% +$67M 0.02% 635
2023
Q4 		$50.1M Sell
4,671,213
-1,680,109
-26% -$14.5M ﹤0.01% 1290
2023
Q3 		$64M Buy
6,351,322
+1,288,526
+25% +$14.9M 0.01% 1158
2023
Q2 		$60.1M Sell
5,062,796
-77,848
-2% -$1.04M 0.01% 1206
2023
Q1 		$62.2M Sell
5,140,644
-465,216
-8% -$7.74M 0.01% 1171
2022
Q4 		$73.8M Sell
5,605,860
-641,532
-10% -$9.39M 0.01% 1088
2022
Q3 		$84.6M Buy
6,247,392
+421,688
+7% +$5.63M 0.01% 1018
2022
Q2 		$71.1M Buy
5,825,704
+148,778
+3% +$1.76M 0.01% 1104
2022
Q1 		$81.4M Buy
5,676,926
+685,524
+14% +$11.2M 0.01% 1164
2021
Q4 		$98.5M Buy
4,991,402
+1,375,971
+38% +$28.8M 0.01% 1111
2021
Q3 		$78.2M Buy
3,615,431
+1,771,867
+96% +$51M 0.01% 1212
2021
Q2 		$46M Buy
+1,843,564
New +$41.1M ﹤0.01% 1471

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments's JANX Position: Q2 2026 in Review

Fidelity Investments reduced its Janux Therapeutics (JANX) stake by 4.8% in Q2 2026, selling an estimated $1.78M and leaving 2,412,825 shares worth $37.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1642.

Fidelity Investments first reported a position in JANX in Q2 2021 and has held it in 21 quarters since. The position peaked at $464M in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Fidelity Investments held 2,412,825 shares of Janux Therapeutics worth $37.1M as of Q2 2026.
  • Fidelity Investments sold 122,899 Janux Therapeutics shares in Q2 2026, an estimated $1.78M.
  • Janux Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1642 holding.
  • Fidelity Investments first reported a position in Janux Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Fidelity Investments's Janux Therapeutics position peaked at $464M in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.